- Email: [email protected]
Metabolomics in prostate cancer diagnosis
8th European Multidisciplinary Meeting on Urological Cancers, 24-27 November 2016, Milan, Italy
P066
Metabolomics in prostate cancer diagnosis Eur Urol Suppl 2016; 15(13);e1641
Gomez Gomez E.1, Fernández-Peralbo M.A.2, Carrasco-Valiente J.1, Calderón-Santiago M.2, RuizGarcía J.1, Priego-Capote F.2, Luque De Castro M.D.2, Requena-Tapia M.J.1 1
Reina Sofia University Hospital/IMIBIC, Dept. of Urology, Cordoba, Spain, 2IMIBIC/ Reina Sofía University Hospital, Dept. of Analytical Chemistry, Cordoba, Spain INTRODUCTION & OBJECTIVES: The accurate detection of Prostate Cancer (PCa) is urgently needed to reduce overdiagnosis and over-treatment, while maintaining a reduction in mortality. In this sense, the existing clinical biomarkers for PCa diagnosis are far from ideal such as the Prostate Specific Antigen serum (PSA) level that suffers from lack of specificity, providing frequent false positives. For this reason, minimum invasive tests in biological samples such blood or urine based on more sensitive and specific biomarkers that can complement or replace PSA represents a goal in PCa research. Recent advancements in analytical instrumentation have made possible the development of metabolomics, providing an insight into the metabolic state and the biochemical processes of the organism. MATERIAL & METHODS: In this research we applied a comprehensive global analysis by liquidchromatography – quadrupole time of flight (LC–QTOF) of urine from 62 patients with a clinically significant PCa and 42 healthy individuals, both groups confirmed by biopsy. Morning urine samples without prostate stimulation were collected from patients before undergoing prostate biopsy. RESULTS: A t-test unpaired (p-value<0.05) provided 42 significant metabolites tentatively identified in urine, that were considered to develop a Partial Least Squares–Discriminant Analysis (PLS–DA) model, characterized by 86.05 and 92.85% of sensitivity and specificity, respectively. Then, an external validation using the 30% of the samples reported a sensitivity and specificity of 73.68% and 78.57%, respectively. These 42 urinary metabolites are involved in biochemical pathways like amino acids metabolism such as lysine degradation, taurine, and tryptophan metabolism, as well as urea cycle and purine and pyrimidine metabolism, among others. These results indicate that deregulation of amino acids metabolism may be specific for PCa metabolic phenotype, which can be also associated with abnormal cell growth and intensive cell proliferation. CONCLUSIONS: These results indicate that deregulation of amino acids metabolism may be specific for prostate cancer metabolic phenotype.Also, they emphasize the necessity of a large scale study to validate the proposed metabolites.
Eur Urol Suppl 2016; 15(13);e1641 Powered by TCPDF (www.tcpdf.org)
P066
Metabolomics in prostate cancer diagnosis Eur Urol Suppl 2016; 15(13);e1641
Gomez Gomez E.1, Fernández-Peralbo M.A.2, Carrasco-Valiente J.1, Calderón-Santiago M.2, RuizGarcía J.1, Priego-Capote F.2, Luque De Castro M.D.2, Requena-Tapia M.J.1 1
Reina Sofia University Hospital/IMIBIC, Dept. of Urology, Cordoba, Spain, 2IMIBIC/ Reina Sofía University Hospital, Dept. of Analytical Chemistry, Cordoba, Spain INTRODUCTION & OBJECTIVES: The accurate detection of Prostate Cancer (PCa) is urgently needed to reduce overdiagnosis and over-treatment, while maintaining a reduction in mortality. In this sense, the existing clinical biomarkers for PCa diagnosis are far from ideal such as the Prostate Specific Antigen serum (PSA) level that suffers from lack of specificity, providing frequent false positives. For this reason, minimum invasive tests in biological samples such blood or urine based on more sensitive and specific biomarkers that can complement or replace PSA represents a goal in PCa research. Recent advancements in analytical instrumentation have made possible the development of metabolomics, providing an insight into the metabolic state and the biochemical processes of the organism. MATERIAL & METHODS: In this research we applied a comprehensive global analysis by liquidchromatography – quadrupole time of flight (LC–QTOF) of urine from 62 patients with a clinically significant PCa and 42 healthy individuals, both groups confirmed by biopsy. Morning urine samples without prostate stimulation were collected from patients before undergoing prostate biopsy. RESULTS: A t-test unpaired (p-value<0.05) provided 42 significant metabolites tentatively identified in urine, that were considered to develop a Partial Least Squares–Discriminant Analysis (PLS–DA) model, characterized by 86.05 and 92.85% of sensitivity and specificity, respectively. Then, an external validation using the 30% of the samples reported a sensitivity and specificity of 73.68% and 78.57%, respectively. These 42 urinary metabolites are involved in biochemical pathways like amino acids metabolism such as lysine degradation, taurine, and tryptophan metabolism, as well as urea cycle and purine and pyrimidine metabolism, among others. These results indicate that deregulation of amino acids metabolism may be specific for PCa metabolic phenotype, which can be also associated with abnormal cell growth and intensive cell proliferation. CONCLUSIONS: These results indicate that deregulation of amino acids metabolism may be specific for prostate cancer metabolic phenotype.Also, they emphasize the necessity of a large scale study to validate the proposed metabolites.
Eur Urol Suppl 2016; 15(13);e1641 Powered by TCPDF (www.tcpdf.org)